Fig 1: Expression of PD-L1, CD4, CD8, CD276 and SOCS3 in hepatocellular carcinoma. Representative immunohistochemical staining and Kaplan-Meier survival curves for CD4, CD8, PD-L1, CD276 and SOCS3 in hepatocellular Carcinoma. (A) CD4 low-expression; (B) CD4 high-expression; (C) No significant difference between the overall survival rate for patients with CD4 high-expression and that for patients with CD4 low-expression (p=0.478); (D) CD8 low-expression; (E) CD8 high- expression; (F) The overall survival rate for patients with CD8 high-expression was significantly higher than that for patients with CD8 low-expression (p=0.002); (G) No significant difference between the overall survival rate for patients with CD4/CD8 low-expression and that for patients with the other (p=0.100); (H) PD-L1 low-expression; (I) PD-L1 high-expression; (J) The overall survival rate for patients with PD-L1 low-expression was significantly higher than that for patients with PD-L1 high-expression (p=0.003); (K) CD276 low-expression; (L) CD276 high-expression; (M) No significant difference between the overall survival rate for patients with CD276 high-expression and that for patients with CD276 low-expression (p=0.166); (N) SOCS3 low-expression; (O) SOCS3 high-expression; (P) The overall survival rate for patients with SOCS3 high-expression was significantly higher than that for patients with SOCS3 low-expression (p=0.015). CD4 and SOCS3 expression statuses in hepatocellular carcinoma tissues and paracancerous tissues were obtained from GSE102079 and GSE121248. (Q) CD4 expression levels of cancerous tissues were significantly downregulated compared with the paracancerous and normal tissues (P<0.001); (R) SOCS3 expression levels of cancerous tissues were significantly downregulated compared with the paracancerous and normal tissues (P<0.001).
Supplier Page from MilliporeSigma for Anti-CD276 antibody produced in rabbit